ClinicalTrials.gg
RecruitingNCT06370988TRIBEUpdated Oct 6, 2026

Theta-Burst Stimulation for Bipolar Depression

An interventional study of iTBS Stimulation and Sham iTBS Stimulation in Bipolar Depression, Bipolar Disorder and Treatment- Resistant Bipolar Disorder, sponsored by Centre for Addiction and Mental Health. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 6, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Bipolar Disorder by Centre for Addiction and Mental Health — 5 open to participants now, 5 under way, none of them phase 3. Bipolar Disorder · Centre for Addiction and Mental Health.

Planned enrollment
3rd of 17
124 · median 70
Started
2024
with 1 other
No phase
17 of 17
5 open now
Registered
15th of 17
by date

Among the 17 studies in Bipolar Disorder by Centre for Addiction and Mental Health, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2024, is one of 17 with no phase, and was the 15th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

5 of the 17 studies in Bipolar Disorder by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Bipolar Disorder by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

The purpose of this trial is to determine if intermittent theta-burst stimulation (iTBS) can reduce the symptoms of depression in treatment-resistant bipolar disorder. To do this, some of the participants in this study will receive treatment with active iTBS stimulation, while others will receive sham iTBS stimulation. Participants will come for 30 days of either active iTBS or sham iTBS, with a 6-week follow-up period. Symptoms of depression (for determining treatment efficacy) and mania (for determining treatment safety) will be assessed using the 17-item Hamilton Rating Scale for Depression (HRSD-17) and the Young Mania Rating Scale (YMRS) every five treatments during the treatment course, and at 1 week and 6 week after treatment completion.

03

Conditions studied

  • Bipolar Depression
  • Bipolar Disorder
  • Treatment- Resistant Bipolar Disorder
  • Type 2 Bipolar Disorder

Browse trials for

Keywords

  • Transcranial Magnetic Stimulation
  • Repetitive Transcranial Magnetic Stimulation
  • rTMS
  • iTBS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The participant must meet all of the inclusion criteria to eligible for this clinical trial:

  1. Must be deemed to have capacity to provide ;
  2. Must be an outpatient
  3. Have a DSM 5 diagnosis of bipolar disorder (type I or II), current episode depressed confirmed by Mini-International Neuropsychiatric Interview version 7.0.2 (MINI);
  4. Age 18-65;
  5. failure to achieve a clinical response to ≥1 adequate treatment trial for bipolar depression based on the Antidepressant Treatment History Form - Short Form (ATHF-SF) OR unable to tolerate at least 2 separate inadequate treatment trials for bipolar depression;43
  6. moderately severe depression with a score ≥ 15 on the PHQ-9;44
  7. not currently experiencing a mixed or manic episode (YMRS ≤10);
  8. no increase or initiation of psychotropic medication with intention of treating depressive symptoms in the 4 weeks prior to screening. This excludes targeted treatment of insomnia with trazodone, melatonin, low-dose doxepin [3-6mg], low-dose benzodiazepines [≤2mg lorazepam daily equivalent], non-benzodiazepine benzodiazepine receptor agonists, or orexin antagonists;
  9. able to adhere to the treatment schedule;
  10. pass the TMS adult safety screening questionnaire.45

Exclusion criteria

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this clinical trial:

  1. have a history of MINI diagnosis of a substance use disorder (other than nicotine and/or caffeine) within the last 3 months;
  2. have a concomitant major unstable medical illness;
  3. have active suicidal intent (assessed during HRSD-17 Item 3 and SSRS as imminent intent to act on specific plan, confirmed by psychiatric staff);
  4. are pregnant or intend to get pregnant during the study;
  5. have a lifetime MINI diagnosis of schizophrenia or schizoaffective disorder;
  6. have psychotic symptoms within the current episode;
  7. have a MINI anxiety disorder, trauma-related disorder, obsessive compulsive disorder, or personality disorder assessed by a study investigator to be primary and/or causing greater impairment than BD-DE;
  8. failure of an adequate acute course of ECT as defined by ATHF-SF during the current episode;
  9. have received any rTMS before due to potential to compromise blinding of treatment allocation;
  10. have any neurological disorder (e.g., recent major cerebrovascular accident), or any history of seizure except those therapeutically induced by ECT or with clear precipitant (e.g., febrile seizure of childhood, alcohol withdrawal, etc.);
  11. have any intracranial implant (e.g., aneurysm clips, shunts, stimulators,) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
  12. are participating in psychotherapy for less than 3 months. Patients will be permitted if they have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study;
  13. are currently taking lorazepam >2 mg daily (or equivalent) due to the potential to limit rTMS efficacy;
  14. are currently taking any dose of an anticonvulsant due to the potential to limit rTMS efficacy. If anticonvulsants have been discontinued prior to screening, at least 5 half-lives have elapsed until screening to allow sufficient drug clearance;
  15. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
124 participants (estimated)

Study arms

  • Sham comparator
    Sham iTBS Stimulation

    Administered once daily over 30 days, using a sham coil that reproduces auditory and tactile sensations of stimulation and has an identical external appearance. Each session will deliver 600 pulses of sham iTBS in triplet 50Hz bursts, repeated at 5Hz 2s on 8s off for a total time of \~3 minutes, 9 seconds at a target intensity of 120% of the subject's resting motor threshold.

    Device: Sham iTBS Stimulation

  • Experimental
    Active iTBS Stimulation

    Administered once daily over 30 days. Each session will deliver 600 pulses of active iTBS in triplet 50Hz bursts, repeated at 5Hz 2s on 8s off for a total time of \~3 minutes, 9 seconds at a target intensity of 120% of the subject's resting motor threshold.

    Device: iTBS Stimulation

Interventions

  • DeviceiTBS Stimulation

    Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30

  • DeviceSham iTBS Stimulation

    Fluid-Cooled B70 A/P Coil with either Magventure X100 or R30

06

What researchers measure

Primary outcomes

  1. Change on the 17-item Hamilton Rating Scale for Depression (HRSD-17)

    Change on the 17-item Hamilton Rating Scale for Depression (HRSD-17), ITT, 6 weeks (completion of treatment phase (30 txs)). The main effect of interest is the interaction term between time since starting treatment and treatment allocation. This analytic approach incorporates longitudinal depressive symptom assessments throughout the trial rather solely at treatment completion.

    Time frame: From enrollment to 6 weeks post-treatment

Secondary outcomes

  1. Symptoms of Mania

    Safety of rTMS in BD-DE with respect to symptoms of mania, Young Mania Rating Scale (YMRS), Safety Outcomes, 6 weeks (completion of treatment phase (30 txs)). The main effect of interest is the interaction term between time since starting treatment and treatment allocation. This analytic approach incorporates longitudinal depressive symptom assessments throughout the trial rather solely at treatment completion.

    Time frame: From enrollment to 6 weeks post-treatment

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2029, 60 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 60 months is above that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
Apr 17, 2024
StartActual
May 15, 2024
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: E•••@camh.ca · •••8501→H•••@camh.ca · •••8501. See the current contact
Oct 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Centre for Addiction and Mental Health · Toronto, CanadaContact E•••@camh.ca · •••8501→h•••@camh.ca · •••8501
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Contact Study contact changed: E•••@camh.ca · •••8501→H•••@camh.ca · •••8501. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Centre for Addiction and Mental Health · Toronto, CanadaContact E•••@camh.ca · •••8501→h•••@camh.ca · •••8501
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06370988
Responsible party
Tyler Kaster (Scientist, Centre for Addiction and Mental Health) — Principal investigator
First posted
Apr 17, 2024
Start date
May 15, 2024
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Hannah Taalman
Contact
Hannah.Taalman@camh.ca
416-535-8501
Mawahib Semeralul
Contact
mawahib.semeralul@camh.ca
416-535-8501 ext. 30210

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion